PRLD - Wall Street Estimates - Prelude Therapeutics Incorporated

Healthcare - Biotechnology - NASDAQ - US

$ 1.1857

-0.361 %

$ 65.3 M

Market Cap

-0.67

P/E

Price Target Average

321.69%

Revenue Forecast Estimate

-0.00%

EBIT Estimate

25.99%

Net Income Estimate

14.54%

WALL STREET ESTIMATES

Wall Street Analysts Price Targets Prelude Therapeutics Incorporated

Wall Street analysts predict an average 1-year price target for PRLD of $5 , with forecasts ranging from a low of $3 to a high of $7 .

PRLD Lowest Price Target Wall Street Target

3 USD 153.02%

PRLD Average Price Target Wall Street Target

5 USD 321.69%

PRLD Highest Price Target Wall Street Target

7 USD 490.37%

REVENUE FORECAST

EBIT FORECAST

NET INCOME FORECAST

Free